Dihexa

Also known as: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide

A potent cognitive enhancer derived from angiotensin IV.

Overview

Dihexa is a small peptide analog of angiotensin IV that is reportedly millions of times more potent than BDNF at promoting neuronal connectivity. It was developed for cognitive disorders.

Mechanism of Action

Activates hepatocyte growth factor (HGF) / c-Met pathway, dramatically enhancing synaptic connectivity. Promotes dendritic spine formation and memory consolidation.

Pharmacokinetics

Highly brain-penetrant. Oral bioavailability claimed. Long-lasting effects on synaptic plasticity.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

Research

Dose

10-20 mg

Frequency

Once daily

Duration

2-4 weeks

Sublingual or oral; extreme caution advised

Stacking Recommendations

Peptides that may be combined based on complementary mechanisms in research settings.

Rationale: Cognitive enhancement

Synergy: Multiple neuroplasticity mechanisms

Research Areas

Cognitive ImpairmentAlzheimer's DiseaseDementiaMemory Enhancement

Key Research Findings

  • 1Restored cognitive function in animal dementia models
  • 2Enhanced synaptic connectivity at picomolar concentrations
  • 3Oral activity claimed (unusual for peptides)
  • 4Long-lasting cognitive improvements after treatment cessation

Side Effects & Contraindications

Reported Side Effects

  • Unknown - limited data

Contraindications

  • Unknown - use extreme caution

Safety Considerations

Very limited safety data. Extreme potency raises concerns. Not approved for human use.

Storage Requirements

Store at -20C

Scientific References

Quick Reference

Sequence
N-hexanoic-Tyr-Ile-(6)aminohexanoic amide
Molecular Weight
421.5 g/mol
Half-Life
Unknown
Bioavailability
Claimed oral activity
Research Stage
preclinical
Administration
Oral or subcutaneous